The levels of the RNA binding protein Hu antigen R determine the druggability of the neddylation pathway in liver cancer

Chantar, M.L.M.; Torres, Lucía Barbier; Ramos, David

doi:10.14800/rd.1123

Cited by 1 publication

(1 citation statement)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Finally, the NEDDylation inhibitor Pevonedistat was shown to exert antitumoral effects in vitro and in vivo in liver cancer, partially through HuR destabilization. Importantly, overexpression of HuR in hepatoma cells offered resistance to pharmacological NEDDylation inhibition, while low levels of HuR sensitized cells to the treatment, suggesting that HuR levels determine the druggability of the NEDDylation pathway in HCC [ 224 ].…”

Section: Therapeutic Approaches To Inhibit Hur In Hepatobiliary Tumorsmentioning

confidence: 99%

Hu Antigen R (HuR) Protein Structure, Function and Regulation in Hepatobiliary Tumors

Lachiondo‐Ortega

Delgado

Baños-Jaime

et al. 2022

Cancers

View full text Add to dashboard Cite

Hu antigen R (HuR) is a 36-kDa ubiquitous member of the ELAV/Hu family of RNA-binding proteins (RBPs), which plays an important role as a post-transcriptional regulator of specific RNAs under physiological and pathological conditions, including cancer. Herein, we review HuR protein structure, function, and its regulation, as well as its implications in the pathogenesis, progression, and treatment of hepatobiliary cancers. In particular, we focus on hepatocellular carcinoma (HCC) and cholangiocarcinoma (CCA), tumors where the increased cytoplasmic localization of HuR and activity are proposed, as valuable diagnostic and prognostic markers. An overview of the main regulatory axes involving HuR, which are associated with cell proliferation, invasion, metastasis, apoptosis, and autophagy in HCC, is provided. These include the transcriptional, post-transcriptional, and post-translational modulators of HuR function, in addition to HuR target transcripts. Finally, whereas studies addressing the relevance of targeting HuR in CCA are limited, in the past few years, HuR has emerged as a potential therapeutic target in HCC. In fact, the therapeutic efficacy of some pharmacological inhibitors of HuR has been evaluated, in early experimental models of HCC. We, further, discuss the major findings and future perspectives of therapeutic approaches that specifically block HuR interactions, either with post-translational modifiers or cognate transcripts in hepatobiliary cancers.

show abstract

Section: Therapeutic Approaches To Inhibit Hur In Hepatobiliary Tumorsmentioning

confidence: 99%

Hu Antigen R (HuR) Protein Structure, Function and Regulation in Hepatobiliary Tumors

Lachiondo‐Ortega

Delgado

Baños-Jaime

et al. 2022

Cancers

View full text Add to dashboard Cite

show abstract

The levels of the RNA binding protein Hu antigen R determine the druggability of the neddylation pathway in liver cancer

Cited by 1 publication

References 29 publications

Hu Antigen R (HuR) Protein Structure, Function and Regulation in Hepatobiliary Tumors

Hu Antigen R (HuR) Protein Structure, Function and Regulation in Hepatobiliary Tumors

Contact Info

Product

Resources

About